American Academy of CME

Ace the Case: Newly Diagnosed AML: Can Molecular Markers Direct Treatment?

Overview / Abstract:	Knowledge of the key management issues for patients with AML is critical. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications.
Expiration	Feb 23, 2024
Discipline(s)	Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME
Format	Online
Credits / Hours	.25
Accreditation	ACCME, ANCC, ACPE, MOC
Presenters / Authors / Faculty	Naval G. Daver, MD Associate Professor Director, Leukemia Research Alliance Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, TX Annie Lattanzio Hale, MSN, RN, OCN Oncology Nurse Navigator Ann B. Barshinger Cancer Institute Lancaster, PA Megan May, PharmD, BCOP Clinical Oncology Pharmacy Specialist Baptist Health Lexington Cancer Center Lexington, KY
Sponsors / Supporters / Grant Providers	This educational activity is supported by an educational grant from AbbVie.
Keywords / Search Terms	American Academy of CME acute myeloid leukemia older adults hematology Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map